Hou Yingwen, Liu Ruibao, Cui Yali, Liu Yan, Sun Houbin, Yang Yi, Yin Linan
Department of Interventional Radiology, Harbin Medical University Cancer Hospital, Harbin, China.
J Contemp Brachytherapy. 2022 Apr;14(2):148-156. doi: 10.5114/jcb.2022.115194. Epub 2022 Apr 1.
To evaluate short-term effectiveness and safety of computed tomography (CT)-guided radioactive iodine-125 (I) seed implantation (CTRISI) for treating adrenal metastases.
A total of 50 consecutive patients with adrenal metastases were enrolled retrospectively. Among them, 18 patients received CTRISI, and 18 received 3D-conformal radiotherapy (3D-CRT) treatment. The remaining 14 patients without any treatments served as a control group. Follow-up CT was performed at 6 weeks, 3 months, and 6 months after treatment. Tumor responses and complications were evaluated.
At 6 weeks, control rate in control group (complete response [CR] + partial response [PR]) was 0, and in the CTRISI group (CR + PR, 84.41%), it was significantly higher than that in the 3D-CRT group (CR + PR, 44.44%). Local control rates with CTRISI at 3 and 6 months were 68.42% and 57.89%, respectively. No severe complications were observed after CTRISI.
CTRISI is an effective and safe method for short-term treatment of adrenal metastases. Our findings suggest that CTRISI can safely and effectively be used for adrenal metastases patients as short-term treatment. Further survival studies with longer follow-up are warranted to validate our results.
评估计算机断层扫描（CT）引导下放射性碘-125（I）粒子植入术（CTRISI）治疗肾上腺转移瘤的短期有效性和安全性。
回顾性纳入50例连续的肾上腺转移瘤患者。其中，18例患者接受CTRISI治疗，18例接受三维适形放疗（3D-CRT）治疗。其余14例未接受任何治疗的患者作为对照组。治疗后6周、3个月和6个月进行随访CT检查。评估肿瘤反应和并发症。
6周时，对照组（完全缓解[CR]+部分缓解[PR]）的控制率为0，CTRISI组（CR+PR，84.41%）显著高于3D-CRT组（CR+PR，44.44%）。CTRISI治疗3个月和6个月时的局部控制率分别为68.42%和57.89%。CTRISI术后未观察到严重并发症。
CTRISI是肾上腺转移瘤短期治疗的一种有效且安全的方法。我们的研究结果表明，CTRISI可安全有效地用于肾上腺转移瘤患者的短期治疗。有必要进行进一步的长期随访生存研究以验证我们的结果。
